Overview

Dashboard News

Insilico Medicine secures 110 million dollars in series E funding round

Insilico Medicine, an AI-driven drug discovery company, has raised $110 million in its Series E funding round, achieving a valuation of over $1 billion. The funding, led by Value Partners Group, will enhance its AI platform and support the clinical development of Rentosertib for idiopathic pulmonary fibrosis, which has completed Phase IIa trials.With a pipeline of 30 drug assets, including 10 approved by the US FDA for investigational use, Insilico also licenses its assets to firms like Fosun Pharma and Exelixis, securing contracts worth approximately $3.5 billion. The company is advancing its proprietary AI system, “pharma.ai,” and developing humanoid robots to automate lab processes.
Tech in Asia
United States Dollar CHN USA Eli Lilly
Healthcare & Medicine, News Article
04:50 13.03.2025

longevity wellness hub secures four million dollars for expansion in gcc

Longevity Wellness Hub has secured $4 million to expand its presence in the GCC, focusing on personalized, frequency-driven wellness solutions. The investment will enhance its patented Advanced Quantum Scanning technology, integrating ancient healing practices with modern biohacking innovations. With plans to launch five new wellness hubs in Dubai, Abu Dhabi, and Riyadh, the company aims to redefine health and recovery through advanced diagnostics and therapies.
Lucidity Insights
United States Dollar ARE SAU Dani Afiouni
Healthcare & Medicine, Press Release
02:12 12.03.2025

Prelude Therapeutics to Showcase Cancer Pipeline at Barclays Healthcare Conference

Prelude Therapeutics will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 12:30 p.m. ET, featuring a fireside chat with CEO Kris Vaddi, M.D. Jane Huang, and CFO Bryant Lim. The company focuses on developing innovative cancer treatments, including first-in-class SMARCA2 degraders, a CDK9 inhibitor, and Precision ADCs through partnerships. A live webcast of the event will be available on their website for 90 days post-presentation.
@StockTitan_net
USA Kris Vaddi Jane Huang Bryant Lim Show more
Healthcare & Medicine, Press Release
13:30 05.03.2025

Raiffeisen donates 750000 francs for new children's hospital in Lucerne

Raiffeisen has donated 750,000 francs to support the construction of a new children's hospital in Lucerne, which aims to acquire a photon counting computed tomography (PCCT) scanner for improved diagnostics with reduced radiation exposure. Set to be completed in 2026, the hospital will be part of a perinatal center alongside a new women's clinic. The initiative is backed by the Central Switzerland Children's Hospital Foundation, with funding originating from the "Spitalstiftung Paul und Gertrud Fischbacher-Labhardt," which has supported pediatric medicine since 1971.
march24.ch
Swiss Franc CHE
Healthcare & Medicine, Press Release
10:18 04.03.2025

Huawei's D2 smartwatch introduces innovative blood pressure monitoring technology

Huawei's Watch D2 is a groundbreaking smartwatch featuring an ambulatory blood pressure monitoring device, certified by China's National Medical Products Association and the EU's Medical Device Regulation. Unlike other smartwatches that require additional equipment for blood pressure tracking, the D2 measures blood pressure continuously over 24 hours, providing valuable insights for those with hypertension and cardiovascular issues.While competitors like Samsung and Apple offer blood pressure functionalities, they rely on external devices or lack measurement capabilities. The blood pressure monitor market is projected to grow significantly, driven by rising health concerns, with potential advancements in Apple's smartwatch lineup also anticipated.
ZDNET
Euro United States Dollar CHN USA Mark Gurman
Healthcare & Medicine, Market Report
21:20 03.03.2025

apple invests in ai and us manufacturing to enhance services

Warren Buffett's latest letter to Berkshire Hathaway shareholders reflects a cautious outlook, emphasizing the importance of responsible fiscal policy as the company holds a significant cash reserve. Meanwhile, Apple announced a $500 billion investment in the U.S. over four years, focusing on manufacturing and AI development, including a new AI server farm in Houston, signaling a shift towards integrating advanced AI capabilities into its ecosystem.
The Motley Fool
USA Dylan Lewis Ricky Mulvey Tim Beyers Robert Barrow Show more
Healthcare & Medicine, Transcript
17:29 03.03.2025

ubs raises price target for lifestance health group to eight fifty

UBS has raised its price target for LifeStance Health Group, Inc. to $8.50 from $7.50 while maintaining a neutral rating. The company specializes in virtual and in-person outpatient mental health care for various conditions, employing around 6,600 mental health professionals across 33 states and over 550 centers.
MarketScreener
LifeStance Health Group Inc. USA
Healthcare & Medicine, Market Report
17:21 03.03.2025

ubs raises treace medical concepts price target to ten dollars maintains neutral rating

UBS has raised the price target for Treace Medical Concepts, Inc. to $10 from $7.90 while maintaining a neutral rating. The company specializes in medical technology for bunion and midfoot deformities, offering patented systems like the Lapiplasty 3D Bunion Correction System and the Adductoplasty Midfoot Correction System, which are designed to improve surgical outcomes and patient recovery. Their products are sold to healthcare providers across the United States.
MarketScreener
Treace Medical Concepts Inc. USA
Healthcare & Medicine, Market Report
17:20 03.03.2025

ubs lowers c4 therapeutics price target while maintaining neutral rating

UBS has lowered its price target for C4 Therapeutics, Inc. to $3.50 from $4 while maintaining a neutral rating. The clinical-stage biopharmaceutical company focuses on targeted protein degradation, utilizing its TORPEDO platform to develop small-molecule medicines, including candidates CFT7455 and CFT1946 for various cancers.
MarketScreener
C4 Therapeutics Inc. USA
Healthcare & Medicine, Market Report
14:26 03.03.2025

Deutsche Bank lowers Denali Therapeutics price target while maintaining buy rating

Deutsche Bank has adjusted its price target for Denali Therapeutics Inc. to $29 from $31 while maintaining a Buy rating. The biopharmaceutical company focuses on developing therapies that can cross the blood-brain barrier for neurodegenerative and lysosomal storage diseases, with seven clinical candidates in development. Key programs include tividenofusp alfa for MPS II, a LRRK2 inhibitor for Parkinson's disease, and an eIF2B activator for ALS, among others.
MarketScreener
DEUTSCHE BANK AG Denali Therapeutics Inc. Biogen Inc. USA Show more
Healthcare & Medicine, Market Report
13:42 03.03.2025
Trending
Subcategory:
Corporate News Industry Trends Startups & Entrepreneurship Stock Market Updates Industry Mergers & Acquisitions Retail and Consumer Goods Finance Mergers & Acquisitions CEO Changes Market Analysis and Predictions Anti-Money Laundering (AML) Regulations Workplace Trends Financial Scams and Security Real Estate Investments Private Equity Deals Supply Chain Management Fintech Startups Telecommunications Laws Central Bank Actions Global Financial Events Consumer Protection Regulations
Countries:
USA IND CHN ARE SAU BEL CHE PRT FRA JPN SGP ISR GBR CAN MYS KOR BRA IDN HKG EGY
Companies:
Knight Frank LLP Mercy Corps Purple Style Labs Ltd. Emirates NBD PAO Godaddy.COM LLC Physicswallah Ltd. Google Inc. Raymond James Financial Inc. Apollo Global Management Wafra Inc. Japan Airlines ARM Holdings Ltd. Central Bank of the UAE Saudi Central Bank International Finance Corporation Corp. Shell Foundation Splunk Inc. State Bank of India Emirates Islamic Bank (PJSC) Dubai Financial Market PJSC
Currencies:
United States Dollar Euro Chinese Yuan Swiss Franc Indian Rupee Japanese Yen United Arab Emirates Dirham Saudi Riyal Egyptian Pound Singapore Dollar British Pound Sterling South Korean Won Indonesian Rupiah Macanese Pataca Hong Kong Dollar Malaysian Ringgit New Taiwan Dollar Omani Rial Australian Dollar
People:
Donald Trump Elon Musk Faisal Durrani Susan Amawi Valerio Ottati Rana Sweis John F. Kennedy Bashar al-Assad Binny Bansal Harmen de Jong Tarik Sektioui Ahmed Yahiaoui Joseph Nye Yun Sungbin Abdulrahman Al Ammar Selina Bieber Howard Lutnick Mike Waltzer Richard Yu Daniel Freund

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings